SBFM (Sunshine Biopharma Inc.) Aset Bersih Perusahaan

Sunshine Biopharma (SBFM) generates revenue through the sale of dietary supplements and the development of antitumor agents, with growth potential embedded in pancreatic therapy and a metric of 0.05. The company advances its anti-cancer research through partnerships with research centers, enhancing its attractiveness for future acquisitions. This price chart reflects the asset's dynamics, backed by a team of dedicated scientists and hired compliance experts.

For Sunshine Biopharma (SBFM), whose oncology developments are currently in a stage of technological lull, an analysis of the firm's balance sheet capital allows for an assessment of real financial stability during the restructuring period. This indicator is calculated as the difference between equity and debt obligations, determining the actual asset backing of each share and signaling to the investor the degree of degradation or preservation of the business's tangible assets.